secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2024-02-01T23:59:59+00:00
Accession:  0001193125-24-021953
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA grants Rare Pediatric Disease Designation to Tyra Biosciences' TYRA-300 for achondroplasia
--------------------------------------------------------------------------------

- FDA granted Rare Pediatric Disease Designation to TYRA-300, an oral FGFR3 inhibitor, for achondroplasia.
- If NDA approved, Tyra may receive a Priority Review Voucher (PRV) that can be sold or transferred.
- Company plans to submit IND in H2 2024 for a randomized Phase 2 trial in children with achondroplasia.
- RPD Designation is for diseases affecting <200,000 in US and primarily individuals under 18 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000119312524021953/0001193125-24-021953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000119312524021953/d674967d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-021953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer